Vident Investment Advisory LLC Grows Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Vident Investment Advisory LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 48.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 128,942 shares of the biopharmaceutical company’s stock after acquiring an additional 42,292 shares during the quarter. Vident Investment Advisory LLC’s holdings in Gilead Sciences were worth $7,665,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Atria Wealth Solutions Inc. bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $5,008,000. Zullo Investment Group Inc. grew its stake in Gilead Sciences by 1,969.6% during the first quarter. Zullo Investment Group Inc. now owns 476 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 453 shares in the last quarter. Invesco Ltd. increased its holdings in Gilead Sciences by 3.7% in the 1st quarter. Invesco Ltd. now owns 7,703,728 shares of the biopharmaceutical company’s stock valued at $457,987,000 after acquiring an additional 276,005 shares during the last quarter. Achmea Investment Management B.V. lifted its stake in Gilead Sciences by 2.0% in the 1st quarter. Achmea Investment Management B.V. now owns 150,935 shares of the biopharmaceutical company’s stock worth $8,974,000 after purchasing an additional 2,997 shares in the last quarter. Finally, PFS Investments Inc. grew its position in shares of Gilead Sciences by 16.9% during the first quarter. PFS Investments Inc. now owns 294,526 shares of the biopharmaceutical company’s stock valued at $17,510,000 after purchasing an additional 42,683 shares in the last quarter. 78.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research analyst reports. Piper Sandler boosted their target price on Gilead Sciences from $71.00 to $74.00 in a research report on Monday, August 15th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 target price on the stock. SVB Leerink initiated coverage on Gilead Sciences in a research report on Monday, May 23rd. They issued a “market perform” rating and a $68.00 target price on the stock. Morgan Stanley boosted their target price on Gilead Sciences from $63.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, July 15th. Finally, TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Monday, August 15th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $72.40.

Gilead Sciences Trading Up 0.3 %

GILD opened at $65.28 on Friday. The stock has a market cap of $81.82 billion, a price-to-earnings ratio of 19.90, a P/E/G ratio of 0.67 and a beta of 0.31. The stock’s 50 day moving average price is $62.73 and its 200-day moving average price is $61.76. Gilead Sciences, Inc. has a one year low of $57.17 and a one year high of $74.12. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Thursday, September 15th will be paid a dividend of $0.73 per share. The ex-dividend date is Wednesday, September 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.47%. Gilead Sciences’s dividend payout ratio is 89.02%.

Gilead Sciences Profile

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.